Health
Drugmaker Bets on Ozempic-Like Weight Loss Treatment
- Mounjaro brought in $570 million in first-quarter revenue
- Analyst says new weight loss data solidify leadership position
Mounjaro
Photographer: Sandy Huffaker/The Washington Post/Getty ImagesThis article is for subscribers only.
Eli Lilly & Co. is becoming a leader in a new type of diabetes and weight loss treatment that Wall Street says could produce some of the biggest blockbusters of all time.
The Indianapolis, Indiana-based drugmaker said early Thursday that the diabetes drug Mounjaro brought in more than $500 million in revenue in the first quarter, exceeding sales in its first six months on the market.